Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Trial Investigating the Safety and Efficacy of Autologous TAC T Cell Monotherapy, and TAC T Cells in Combination With Pembrolizumab, in Relapsed HER2-Positive Solid Tumors

Next Previous
Search
Trial Profile

A Phase 1/2 Trial Investigating the Safety and Efficacy of Autologous TAC T Cell Monotherapy, and TAC T Cells in Combination With Pembrolizumab, in Relapsed HER2-Positive Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 10 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary) ; TAC01 HER2 (Primary) ; Bendamustine; Clofarabine; Cyclophosphamide; Fludarabine
  • Indications Adenocarcinoma; Advanced breast cancer; Bladder cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; HER2 positive breast cancer; Lung cancer; Male breast cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms TACTIC-2
  • Sponsors Triumvira

    • Most Recent Events

    • 04 Jun 2024 Status changed from active, no longer recruiting to discontinued (Study terminated by Sponsor for commercial reasons).
    • 08 Feb 2024 Status changed from recruiting to active, no longer recruiting.
    • 20 Jan 2024 Results (As of 31 August 2023, n=20) assessing safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors presented at the 2024 Gastrointestinal Cancers Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top